[go: up one dir, main page]

DE60039601D1 - Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit - Google Patents

Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit

Info

Publication number
DE60039601D1
DE60039601D1 DE60039601T DE60039601T DE60039601D1 DE 60039601 D1 DE60039601 D1 DE 60039601D1 DE 60039601 T DE60039601 T DE 60039601T DE 60039601 T DE60039601 T DE 60039601T DE 60039601 D1 DE60039601 D1 DE 60039601D1
Authority
DE
Germany
Prior art keywords
myc
kidney disease
treatment
polycystic kidney
antisense against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60039601T
Other languages
English (en)
Inventor
Patrick L Iversen
John E Mata
Vincent H Gattone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sarepta Therapeutics Inc
University of Kansas Medical Center
Original Assignee
AVI Biopharma Inc
University of Kansas Medical Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AVI Biopharma Inc, University of Kansas Medical Center filed Critical AVI Biopharma Inc
Application granted granted Critical
Publication of DE60039601D1 publication Critical patent/DE60039601D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/314—Phosphoramidates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3233—Morpholino-type ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)
DE60039601T 1999-05-24 2000-05-24 Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit Expired - Fee Related DE60039601D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13563799P 1999-05-24 1999-05-24
PCT/US2000/014220 WO2000071706A1 (en) 1999-05-24 2000-05-24 ANTISENSE TO c-myc FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE

Publications (1)

Publication Number Publication Date
DE60039601D1 true DE60039601D1 (de) 2008-09-04

Family

ID=22468964

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039601T Expired - Fee Related DE60039601D1 (de) 1999-05-24 2000-05-24 Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit

Country Status (8)

Country Link
EP (1) EP1185637B1 (de)
JP (1) JP2003500418A (de)
KR (1) KR100708573B1 (de)
AT (1) ATE402257T1 (de)
AU (1) AU781094B2 (de)
CA (1) CA2374499A1 (de)
DE (1) DE60039601D1 (de)
WO (1) WO2000071706A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1629105B1 (de) 2003-04-29 2010-09-01 AVI BioPharma, Inc. Zusammensetzungen zur verbesserung der antisense-wirksamkeit und des transports von nukleinsäureanalog in zellen
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20050288246A1 (en) 2004-05-24 2005-12-29 Iversen Patrick L Peptide conjugated, inosine-substituted antisense oligomer compound and method
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
US20100016215A1 (en) 2007-06-29 2010-01-21 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
KR20180118828A (ko) * 2008-10-24 2018-10-31 사렙타 쎄러퓨틱스 인코퍼레이티드 Dmd를 위한 다중 엑손 스키핑 조성물
AU2009335740B2 (en) 2008-12-17 2016-04-21 Sarepta Therapeutics, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
US20110269665A1 (en) 2009-06-26 2011-11-03 Avi Biopharma, Inc. Compound and method for treating myotonic dystrophy
JP5717128B2 (ja) * 2010-11-24 2015-05-13 国立大学法人東北大学 染色体優性多発性嚢胞腎の判定方法及び予防・治療薬のスクリーニング方法
US9161948B2 (en) 2011-05-05 2015-10-20 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US9457016B2 (en) 2013-08-29 2016-10-04 New York University Methods for treating polycystic kidney disease
AU2015301278A1 (en) 2014-08-04 2017-02-09 Genzyme Corporation Biomarkers of polycystic kidney disease and uses thereof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
MX2018006250A (es) 2015-11-18 2018-09-05 Genzyme Corp Biomarcador de enfermedad poliquistica renal y usos del mismo.
MX2019006882A (es) 2016-12-19 2019-08-16 Sarepta Therapeutics Inc Conjugados de oligomeros de omision de exon para distrofia muscular.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
CA2069869C (en) * 1989-12-20 1995-12-19 James E. Summerton Uncharged morpholino-based polymers having phosphorous-containing chiral intersubunit linkages

Also Published As

Publication number Publication date
CA2374499A1 (en) 2000-11-30
JP2003500418A (ja) 2003-01-07
EP1185637B1 (de) 2008-07-23
WO2000071706A1 (en) 2000-11-30
ATE402257T1 (de) 2008-08-15
EP1185637A1 (de) 2002-03-13
KR100708573B1 (ko) 2007-04-18
AU781094B2 (en) 2005-05-05
KR20020033628A (ko) 2002-05-07
AU5284300A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
DE60039601D1 (de) Antisense gegen c-myc zur behandlung von polyzystischer nierenkrankheit
DE60023043D1 (de) (S,S)-Reboxetin zur Behandlung von Inkontinenz
DE69822665D1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa-4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14-dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
DE60219793D1 (de) Methode zur behandlung von zytokinvermittelten erkrankungen
ATE487493T1 (de) Azolsäure-derivate, allein oder kombiniert, zur behandlung von diabetes und dyslipidaemien; und zur behandlung von malignen erkrankungen
DE69818058D1 (de) Verwendung von polyallylamin-polymeren zur herstellung eines medikamentes zur behandlung von hypercholesterolemia
ATE250576T1 (de) Substituierte pyrrolylverbindungen zur behandlung von entzündungen
DE69626864D1 (de) Abwasserbecken ZUR AEROBEN BEHANDLUNG VON ABWASSER beinhaltend Träger
EP1325019A4 (de) Antisense-modulation der clusterinexpression
DE60029033D1 (de) Verfahren zur Behandlung von Tissuepapier
SE0104248D0 (sv) Method of treatment
EP1123414A4 (de) Antisense modulation der expression von integrin alpha 4
DE69912432D1 (de) Zur behandlung von krebs nützliche thiophen- und furan-2,5-dicarboxamide
DE69834724D1 (de) Behandlung von Darm- oder Blasenentzündungen
ATE246518T1 (de) Egr-1 zur herstellung eines medikamentes zur behandlung von wunden
DE60044160D1 (de) Behandlung von Inkontinenz
PT1237562E (pt) Processo de preparacao de extractos de micania contendo micanolida e di-hidromicanolida e utilizacao no tratamento das doencas proliferativas
DE59902666D1 (de) Edelfosin zur behandlung von hirntumoren
ATE298246T1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DE60026883D1 (de) Methoden und zusammensetzungen zur behandlung von schmerzen
NO20032406L (no) Anvendelse av 1-fenyl-3-dimetylaminopropanforbindelser for behandling av urininkontinens
DE50100833D1 (de) Verwendung von 2-methyl-thiazolidin-2,4-dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
EA200200948A1 (ru) Лечение псориаза
BR0115880A (pt) Emprego de compostos ciclohexanona de 6-dimetilaminometila-1-fenil para o tratamento da incontinência urinária
DK1368023T3 (da) Anvendelse af buprenoprphin til behandling af urininkontinens

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee